EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 10 (Octobre 2009) Med Sci (Paris), 25 10 (2009) 785-788 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 10, Octobre 2009
Page(s) 785 - 788
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20092510785
Published online 15 October 2009
  1. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6 : 587–96. [Google Scholar]
  2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 8 : 8. [Google Scholar]
  3. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med 2008; 359 : 722–34. [Google Scholar]
  4. Nimer SD. Myelodysplastic syndromes. Blood 2008; 111 : 4841–51. [Google Scholar]
  5. Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol 2008; 19 : 385–93. [Google Scholar]
  6. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia 2008; 22 : 1841–8. [Google Scholar]
  7. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360 : 2289–301. [Google Scholar]
  8. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23 : 900–4. [Google Scholar]
  9. Tefferi A, Lim KH, Abdel-Wahab O, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23 : 1343–5. [Google Scholar]
  10. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23 : 905–11. [Google Scholar]
  11. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114 : 144–7. [Google Scholar]
  12. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 13 : 13. [Google Scholar]
  13. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113 : 6403–10. [Google Scholar]
  14. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41 : 838–42. [Google Scholar]
  15. Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17 : 637–41. [Google Scholar]
  16. Ono R, Taki T, Taketani T, et al. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002; 62 : 4075–80. [Google Scholar]
  17. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324 : 930–5. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.